Generate Investment Management Ltd bought a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 42,042 shares of the medical research company's stock, valued at approximately $8,262,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Smith Group Asset Management LLC acquired a new stake in shares of IQVIA during the fourth quarter valued at about $1,616,000. Simplify Asset Management Inc. grew its stake in IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company's stock valued at $2,284,000 after purchasing an additional 3,894 shares in the last quarter. Nordea Investment Management AB increased its holdings in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after purchasing an additional 452,029 shares during the last quarter. Fifth Third Bancorp boosted its stake in shares of IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock valued at $2,590,000 after buying an additional 1,521 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after buying an additional 583,396 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at IQVIA
In related news, Director John G. Danhakl bought 1,275 shares of the business's stock in a transaction on Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.60% of the stock is currently owned by insiders.
IQVIA Price Performance
IQVIA stock traded down $6.03 during trading hours on Tuesday, hitting $200.94. 1,380,704 shares of the company traded hands, compared to its average volume of 1,425,459. The firm's 50-day simple moving average is $200.77 and its two-hundred day simple moving average is $219.09. The firm has a market cap of $36.47 billion, a P/E ratio of 26.79, a P/E/G ratio of 2.25 and a beta of 1.48. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.
IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.81 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on IQV shares. Morgan Stanley upped their target price on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday. Leerink Partners reaffirmed an "outperform" rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Stephens assumed coverage on IQVIA in a research report on Friday, December 20th. They set an "overweight" rating and a $250.00 price target on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $270.00 price objective on shares of IQVIA in a report on Monday. Finally, StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a report on Thursday, November 28th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and a consensus price target of $251.67.
Check Out Our Latest Analysis on IQVIA
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
